World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
146
Citations
80820
World Ranking
1338
National Ranking
775

Overview

Kwok-Kin Wong is affiliated with New York University in the United States and has an extensive research portfolio primarily focused on medicine and biochemistry, genetics, and molecular biology. Their scholarly output includes publications in key subfields such as molecular biology, oncology, pulmonary and respiratory medicine, cancer research, and immunology.

Their main areas of research encompass lung cancer treatments and mutations, cancer immunotherapy and biomarkers, epigenetics and DNA methylation, lung cancer research studies, RNA modifications and cancer, cancer genomics and diagnostics, and cancer related to hypoxia and metabolism.

Kwok-Kin Wong has contributed to multiple prominent journals and publication venues. Among the most frequent are UNC Libraries, bioRxiv (Cold Spring Harbor Laboratory), Cancer Research, Cancer Cell, and the Journal of Thoracic Oncology.

The collaborative nature of their work is reflected in frequent co-authorship with researchers such as Jiehui Deng, Ting Chen, Aristotelis Tsirigos, Hongbin Ji, and John T. Poirier.

Selected recent papers include:

  • The current state of the art and future trends in RAS-targeted cancer therapies, 2022, Nature Reviews Clinical Oncology
  • Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway, 2020, Cancer Cell
  • PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer, 2020, Nature Immunology
  • SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling, 2020, The Journal of Experimental Medicine
  • Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis, 2020, JNCI Journal of the National Cancer Institute

Best Publications

  • A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

    Sreenath V. Sharma;Diana Y. Lee;Bihua Li;Margaret P. Quinlan

  • The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

    Cai-Hong Yun;Kristen E. Mengwasser;Angela V. Toms;Michele S. Woo

  • Non-small-cell lung cancers: a heterogeneous set of diseases

    Zhao Chen;Christine M. Fillmore;Peter S. Hammerman;Carla F. Kim

  • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

    D Li;L Ambrogio;L Ambrogio;T Shimamura;S Kubo

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

    Jeffrey A. Engelman;Jeffrey A. Engelman;Liang Chen;Xiaohong Tan;Katherine Crosby

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

    Gang Lu;Richard E. Middleton;Huahang Sun;MarkVic Naniong

  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Esra A. Akbay;Esra A. Akbay;Shohei Koyama;Julian Carretero;Abigail Altabef;Abigail Altabef

  • LKB1 modulates lung cancer differentiation and metastasis

    Hongbin Ji;Matthew R. Ramsey;D. Neil Hayes;Cheng Fan

  • Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

    Wenjun Zhou;Dalia Ercan;Liang Chen;Cai-Hong Yun

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

    Ji Luo;Michael J. Emanuele;Danan Li;Chad J. Creighton

  • SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

    Adam J. Bass;Adam J. Bass;Hideo Watanabe;Hideo Watanabe;Craig H. Mermel;Craig H. Mermel;Soyoung Yu

  • EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

    Wendy Béguelin;Relja Popovic;Matt Teater;Yanwen Jiang

  • PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits

  • Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

    Yong Jia;Cai-Hong Yun;Eunyoung Park;Dalia Ercan

  • The dTAG system for immediate and target-specific protein degradation

    Behnam Nabet;Justin M. Roberts;Dennis L. Buckley;Dennis L. Buckley;Joshiawa Paulk;Joshiawa Paulk

  • Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth

    A McGarry Houghton;Danuta M Rzymkiewicz;Hongbin Ji;Alyssa D Gregory

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

Frequent Co-Authors

Pasi A. Jänne
Pasi A. Jänne Harvard University
Matthew Meyerson
Matthew Meyerson Harvard University
Nathanael S. Gray
Nathanael S. Gray Stanford University
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University
Hongbin Ji
Hongbin Ji Chinese Academy of Sciences
Heidi Greulich
Heidi Greulich Broad Institute
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Carla F. Kim
Carla F. Kim Boston Children's Hospital
Nabeel Bardeesy
Nabeel Bardeesy Harvard University
Scott J. Rodig
Scott J. Rodig Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always mean following the traditional path of becoming a physician. There are a wide range of related healthcare careers that can be pursued through flexible online degree programs.

For those interested in pharmacy, pharm d online programs offer a way to earn advanced credentials while balancing work and study. If you enjoy organizing data and healthcare systems, an online health information management degree can help open doors to administrative and tech-driven roles in hospitals and clinics.

Medical billing and coding is another popular career pathway that focuses on healthcare documentation and insurance. Check out information on medical billing and coding certification cost to find affordable programs. Additionally, becoming a nurse practitioner is a rewarding option for those interested in patient care. Discover some of the cheapest np programs online to advance your nursing career.

With a variety of online healthcare degrees and certification programs, you can find the right pathway to match your interests, schedule, and career goals.

Best Scientists Citing Kwok-Kin Wong

Trending Scientists

Recently Published Articles